Diffuse Optical Imaging (DOI) is a non-invasive optical technique that employs near-infrared (NIR) light to quantitatively characterize the optical properties of thick tissues. Although NIR methods were first applied to breast diaphanography nearly 80 years ago, quantitative DOI methods employing time- or frequency-domain photon migration technologies have only recently been used for breast imaging (i.e. since the mid-1990s). In this research program we propose the formation of a flexible, multi-institutional """"""""Network"""""""" composed of partnerships between leading, Academic, Industry and Government laboratories that have demonstrated expertise in Breast Cancer Research. Our broad goal is to advance new technology, Multi-Dimensional Diffuse Optical Imaging (MDDOI), that will dramatically improve breast cancer detection, clinical management, and quality of life for breast cancer patients. MD-DOI employs broadband technology both in spectral (approximately 650-1000 nm) and temporal (approximately IGHz) domains in order to separate absorption from scattering and quantify multiple molecular probes based on absorption or fluorescence contrast. Additional dimensionality is provided by integrating and co-registering MD-DOI functional information with Magnetic Resonance Imaging (MRI) and X-Ray mammography. Factors affecting critical MD-DOI issues, such as intrinsic and extrinsic conlrast mechanisms, quantitation of biochemical components, image formation/visualization, and multi-modality co-registration will be explored and defined in 3 research projects and delivered as usable translational technologies by three research resource cores. Based on these fmdings, a standardized MD-DOI platform will be developed that can be used as a stand-alone device or in conjunction with MRI and mammography. This technology will be tested, validated, and duplicated for translational use in multiple clinical sites: The University of Pennsylvania, The Massachusetts General Hospital (MGH), Dartmouth University, and The University of California, (Irvine and San Francisco). Clinical studies in each test site will involve coordination through their respective breast care centers housed in five NCI Comprehensive Cancer Centers. Pre-clinlcal animal studies will be performed using specially designed MD-DOI technology optimized for animal models and optical/MR/molecular imaging agents. The proposed Network will stimulate the development, validation, and standardization of new technologies, procedures, and analysis tools; as well as the formation of important multi-institutional collaborative relationships and commercial partners. This broad-based, multi-disciplinary effort will provide the community with new insight regarding the origins of breast disease and practical approaches for addressing several key challenges in breast cancer clinical management, including: detecting early disease, distinguishing between malignant and benign lesions, and understanding the impact of therapies (e.g. hormone replacement therapy (HRT) and neoadjuvant chemotherapy).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (O1))
Program Officer
Baker, Houston
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
Schools of Medicine
United States
Zip Code
Ban, H Y; Schweiger, M; Kavuri, V C et al. (2016) Heterodyne frequency-domain multispectral diffuse optical tomography of breast cancer in the parallel-plane transmission geometry. Med Phys 43:4383
Busch, David R; Choe, Regine; Durduran, Turgut et al. (2014) Blood flow reduction in breast tissue due to mammographic compression. Acad Radiol 21:151-61
Wang, Fusheng; Vergara-Niedermayr, Cristobal; Liu, Peiya (2014) Metadata based management and sharing of distributed biomedical data. Int J Metadata Semant Ontol 9:42-57
Busch, David R; Choe, Regine; Rosen, Mark A et al. (2013) Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express 4:105-21
O'Sullivan, Thomas D; Leproux, Anaïs; Chen, Jeon-Hor et al. (2013) Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res 15:R14
Roblyer, Darren; O'Sullivan, Thomas D; Warren, Robert V et al. (2013) Feasibility of Direct Digital Sampling for Diffuse Optical Frequency Domain Spectroscopy in Tissue. Meas Sci Technol 24:045501
Leproux, Anaïs; Durkin, Amanda; Compton, Montana et al. (2013) Assessing tumor contrast in radiographically dense breast tissue using Diffuse Optical Spectroscopic Imaging (DOSI). Breast Cancer Res 15:R89
Tichauer, K M; Samkoe, K S; Klubben, W S et al. (2012) Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol 57:6647-59
Chung, So Hyun; Yu, Hon; Su, Min-Ying et al. (2012) Molecular imaging of water binding state and diffusion in breast cancer using diffuse optical spectroscopy and diffusion weighted MRI. J Biomed Opt 17:071304
Tichauer, Kenneth M; Samkoe, Kimberley S; Sexton, Kristian J et al. (2012) In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol 14:584-92

Showing the most recent 10 out of 74 publications